IFG Advisory LLC Buys New Shares in Bristol Myers Squibb Company $BMY

IFG Advisory LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 51,811 shares of the biopharmaceutical company’s stock, valued at approximately $2,337,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Brighton Jones LLC increased its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank grew its holdings in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Versor Investments LP purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $371,000. Finally, GPS Wealth Strategies Group LLC raised its holdings in Bristol Myers Squibb by 8.2% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 4,500 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 341 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Top-line Phase 2 results for Reblozyl in alpha‑thalassemia came back positive (primary and key secondary endpoints met; safety consistent with prior data), which strengthens BMY’s late‑stage pipeline optionality and potential label expansion. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Positive Sentiment: Commercial momentum: Reblozyl has topped roughly $2.3B in annualized sales and company commentary plus an AI collaboration (Evinova) to speed trial execution underline both near‑term revenue support and improved R&D efficiency. These items support BMY’s top‑line outlook if label/drug expansion continues. Can Reblozyl Stabilize BMY’s Top Line Amid Legacy Drugs Decline? Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story
• Neutral Sentiment: Round‑up/earnings coverage: BMY appears in lists of Q4 “outperformers” for branded pharma on revenue strength, but underlying EPS dynamics were mixed—investors should read the details rather than rely on headlines. Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
• Neutral Sentiment: Industry context: Strength at peers (e.g., Merck’s Keytruda momentum) highlights competitive dynamics in oncology that influence investor expectations for BMY’s oncology franchises. Merck’s Keytruda Drives its 2025 Revenue Surge: What’s Ahead?
• Neutral Sentiment: Macro/sector themes such as nanomedicine and dividend‑income positioning appeared in recent coverage; these are background drivers but less directly tied to BMY’s immediate price move. Global Nanomedicine Market is Projected Cross
• Negative Sentiment: Market reaction and fundamentals: several news pieces note BMY’s intraday/close decline (broader selling). The core negative catalysts are the Q4 EPS miss (reported EPS below consensus) and FY‑2026 guidance that sits below some analyst forecasts — these credit‑and‑earnings concerns explain why the stock is down despite pipeline positives. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim reissued a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Stock Down 2.6%

Shares of NYSE:BMY opened at $60.69 on Friday. The firm has a market capitalization of $123.59 billion, a P/E ratio of 17.59, a P/E/G ratio of 0.18 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a 50 day moving average price of $57.55 and a 200-day moving average price of $50.91. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.